Review article

Review of the state of the art of acrylamide human biomonitoring

Abel Albiach-DelgadoDepartment of Analytical Chemistry, University of Valencia, Doctor Moliner 50, 46100, Burjassot, SpainFrancesc A. Esteve‐TurrillasDepartment of Analytical Chemistry, University of Valencia, Doctor Moliner 50, 46100, Burjassot, SpainSandra F. FernándezDepartment of Analytical Chemistry, University of Valencia, Doctor Moliner 50, 46100, Burjassot, Spain; Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, FISABIO-Public Health, Av. Catalunya, 21, 46020, Valencia, SpainBorja GarlitoFoundation for the Promotion of Health and Biomedical Research in the Valencian Region, FISABIO-Public Health, Av. Catalunya, 21, 46020, Valencia, SpainOlga PardoDepartment of Analytical Chemistry, University of Valencia, Doctor Moliner 50, 46100, Burjassot, Spain; Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, FISABIO-Public Health, Av. Catalunya, 21, 46020, Valencia, Spain. Electronic address: [email protected]

2022en

ABI

Abstract

Human biomonitoring (HBM) is a very useful tool for assessing human exposure to acrylamide (AA). In the framework of the Human Biomonitoring Initiative (HBM4EU) AA was included in its second list of priority substances due to the potential threat to human health. HBM data on AA are scarce, but the use of specific and sensitive biomarkers represents a reliable indicator of exposure. In this review an overview of available knowledge on HBM of AA is provided in terms of: i) preferred exposure biomarkers and matrices for the HBM of AA; ii) analytical methods for determining its biomarkers of exposure in the most used specimens; iii) current HBM data available; and iv) tools for interpreting HBM data for AA in relation to risk assessment. Finally, future trends in this field are discussed.

Identifiers

DOI: 10.1016/j.chemosphere.2022.133880

Citations and references

Cited by 20 references

Metrics — AkademScholar